Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
The FDA asked, and Eli Lilly and Company delivered. The company now hopes to secure an additional approval for orforglipron/Foundayo that covers the treatment of type 2 diabetes.
Of all lawsuits filed against patients in 2024 in one U.S. state, physician practices and other non-hospital healthcare entities accounted for 80% of cases. That’s a complete inversion from just six years prior.
In the three or so years since it burst into healthcare, ambient AI scribe technology has run away with the win in the market-uptake race. What has been the return on investment in all those software packages?
"This case reflects a troubling pattern in which payers, dissatisfied with IDR results, increasingly try to attack those outcomes outside the framework Congress created," Rad Partners says.
“Expanding residency slots and mitigating workforce attrition will be necessary to mitigate increasing workforce gaps," experts write in the Journal of the American College of Radiology.
Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
